(Q41023513)

25 September 2017

1 reference

title

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review (English)

1 reference

25 September 2017

prostatic hypertrophy

1 reference

Lowe FC

1

1 reference

PubMed ID

8693632

25 September 2017

Ku JC

series ordinal

2

1 reference

PubMed ID

8693632

25 September 2017

language of work or name

English

0 references

publication date

1 July 1996

1 reference

25 September 2017

1 reference

25 September 2017

48

1 reference

25 September 2017

1

1 reference

25 September 2017

12-20

1 reference

Growing use of medicinal botanicals forces assessment by drug regulators

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

The effect of extracts of the roots of the stinging nettle (Urtica dioica) on the interaction of SHBG with its receptor on human prostatic membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Treatment of benign prostatic hyperplasia with phytosterols

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

The value of permixon in benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

The Natural History of Untreated “Prostatism”

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

1 reference

7 January 2021

In vitro Evaluation of the Pollen Extract Cernitin T-60, in the Regulation of Prostate Cell Growth

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Protective effect of Tadenan on bladder function secondary to partial outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

A Clinical and Urodynamic Study of Tadenan in the Treatment of Benign Prostatic Hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

Observations with Bazoton in the management of prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900077-5

7 January 2021

10.1016/S0090-4295(96)00077-5

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8693632